Devan Graves
Psychiatric/Mental Health · Indianapolis, INNPI 1811666761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 646 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 646 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$952
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$881
- plus $5K from 18 others
What the payments were for
- Food & beverage$12,201100%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 146 | $2,198 |
| Neurocrine Biosciences, Inc. | 79 | $1,337 |
| Otsuka America Pharmaceutical, Inc. | 67 | $1,178 |
| Vanda Pharmaceuticals Inc. | 38 | $1,049 |
| Alkermes, Inc. | 48 | $952 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $881 |
| Johnson & Johnson | 38 | $830 |
| Corium, LLC | 37 | $728 |
| Teva Pharmaceuticals USA, Inc. | 33 | $648 |
| Lundbeck LLC | 19 | $415 |
| Noven Therapeutics, LLC | 17 | $375 |
| Bausch Health US, LLC | 14 | $307 |
| Almatica Pharma LLC | 12 | $198 |
| Axsome Therapeutics, Inc. | 7 | $190 |
| Supernus Pharmaceuticals, Inc. | 4 | $182 |
| Idorsia Pharmaceuticals US Inc | 9 | $161 |
| Collegium Pharmaceutical, Inc. | 8 | $144 |
| Merck | 7 | $115 |
| Ironshore Pharmaceuticals Inc. | 6 | $110 |
| Neos Therapeutics, LP | 7 | $109 |
| Tris Pharma Inc | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,250 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 34 | $48,359 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,579 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 126 | $4,190 |
| Aripiprazole | 82 | $1,908 |
| Alprazolam | 255 | $1,655 |
| Dextroamphetamine Sulfate | 14 | $1,472 |
| Prazosin Hcl | 38 | $623 |
| Bupropion XlBupropion Hcl | 76 | $614 |
| Quetiapine Fumarate | 68 | $576 |
| Duloxetine Hcl | 43 | $565 |
| Clonazepam | 77 | $536 |
| Methylphenidate Hcl | 36 | $520 |
| Trazodone Hcl | 51 | $493 |
| Hydroxyzine Pamoate | 26 | $441 |
| Zolpidem Tartrate | 106 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,198 | $48,35934 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $24 | $4,57912 claims |
| Almatica Pharma LLCSertraline Hcl | $198 | $14126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Clyde YanIndianapolis$9K
- Beth DelamboIndianapolis$7K
- Olga Marie JiodioIndianapolis$6K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Trina GreenwaldMarion$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.